Proteome Sciences PLC Director/PDMR Shareholding (2803W)
April 14 2023 - 5:45AM
UK Regulatory
TIDMPRM
RNS Number : 2803W
Proteome Sciences PLC
14 April 2023
14 April 2023
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Investment
Management Pte Ltd ("Vulpes") that on 12 and 13 April 2023 it
purchased, respectively, 100,000 and 100,000 ordinary shares of 1p
in the capital of the Company ("Ordinary Shares") at a price of 4p
per Ordinary Share (the "Purchase"). Following the Purchase, Vulpes
has a total direct and indirect interest in 67,789,772 Ordinary
Shares, equivalent to 22.97% of Proteome Sciences' total issued
share capital.
By virtue of Martin Diggle being a Director of both Vulpes and
the Company, he now has an interest in 67,789,772 Ordinary Shares
of the Company representing 22.97% of the issued share capital of
the Company.
The below notification is made in accordance with the
requirements of the Market Abuse (amendment) (EU Exit) Regulations
2019/310.
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Martin Diggle
----------------------------------------- --------------------------------
Reason for the notification
---------------------------------------------------------------------------
a) Position/status: Non-Executive Director
----------------------------------------- --------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- --------------------------------
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- --------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- --------------------------------
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p nominal
type of instrument: value
Identification code: GB0003104196
----------------------------------------- --------------------------------
b) Nature of the transaction: Purchase of Ordinary Shares
----------------------------------------- --------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
4.00p 100,000
----------
3.90p 100,000
----------
----------------------------------------- --------------------------------
d) Aggregated information: Single transaction as in
* Aggregated volume: 4 c) above Average Volume(s)
Price
3.95p 200,000
* Price: ----------
----------------------------------------- --------------------------------
e) Date of the transaction: 12 and 13 April 2023
----------------------------------------- --------------------------------
f) Place of the transaction: London Stock Exchange,
AIM (XLON)
----------------------------------------- --------------------------------
For further information please contact:
Proteome Sciences plc
Dr. Mariola Soehngen, Chief Executive Tel: +44 (0)20 7043 2116
Officer
Dr. Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer
Abdelghani Omari, Chief Financial Officer
Allenby Capital Limited (Nominated Adviser & Broker)
John Depasquale / Jeremy Porter Tel: +44 (0) 20 3328 5656
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSFUSULEDSEDL
(END) Dow Jones Newswires
April 14, 2023 05:45 ET (09:45 GMT)
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024
